The penny stock of Zenosense, Inc. (ZENO) is on the run based on it having “come up with the simplest, and most necessary medical device innovation ever seen” and its being pumped as possibly being “the best long you’ve ever picked in your portfolio.” Based on claims that ZENO stock “could easily skyrocket from $1 to over $8 in a matter of months,” the call was a bit early considering that the share price is only 0.36, even with The Undervalued Quarterly landing page dedicated to the development stage medical device maker. With $527,000 already applied to development costs and another estimated $1,411,000 due for further research and development of the MRSA sensory device, recipients of the “let’s get rich helping those at risk” advertisement are going to need to buy a ton of shares if that number is ever going to be reached.
Want to crush the Markets and make profits of $624, $2,897, even $40,656?
Click HERE To Make Sure You Don’t Miss Our Penny Stock Alerts!
ZENO Stock Quote
Market Cap: 17.62M
Last: 0.36 ▼ -0.02 (-5.26%)
Volume: 120,893
Dollar Volume: $44,177
Open: 0.38
High: 0.38
Low: 0.355
Trades: 54
14-Day RSI: 57.18%
1st Resistance Point: 0.375
1st Support Level: 0.35
52Wk High: 1.00
52Wk Low: 0.15
Zenosense, for the most part, made its OTC debut just over a month ago, on August 20, when shares of ZENO stock began to trade regularly and have been tinkering around between the 0.25 and 0.50 range. Volume for the wannabe detection device development company based in Valencia, Spain has yet to break the 400,000 mark despite their being no reported beneficial shareholders of more than 10% of the Company’s stock.
Looking back to where Zenosense sprouted up from, the Company obtained their licensing deal with Sgenia Industrial, S.L. and its subsidiaries Sgenia Soluciones, S.L. and ZENON Biosystem, S.L., all of which are formed under the laws of Spain, back on December 4, 2013 for 1,163,212 pre-split shares. At the same time, the Company issued 375,000 pre-split shares of ZENO stock to an investor for cash proceeds of $150,000 and, subsequently, did a 3-for-1 stock dividend, making the investor’s purse 1,125,000 shares with a cost basis of 0.133 per share, a price whereby $1 or better would make the deal worth having been done. Another 423,529 shares were sold on February 4, 2014 for cash proceeds of $180,000.
What Zenosense will now try to do is develop and market devices to detect the MRSA “Super-Bug” and to detect signs of lung cancer in exhaled breath. MRSA is a bacterium responsible for several difficult-to-treat infections in humans better known as any strain of Staphylococcus aureus that has developed a resistance to beta-lactam antibiotics, including the penicilins such as methicillin, dicloxacillin, nafcillin, oxacillin, and also the cephalosporins group.
The landing page, hosted by Undervalued Quarterly, which is most likely to be followed up with some hard mailers being sent out, is calling for ZENO to run well above the $1 range based on nearly 6,000 hospitals all around America that could all rush into ZenoSense’s E-Nose to end this plague which supposedly kills more people in the U.S. annually than AIDS. It would be a wonderful breakthrough in the medical field for such a device to come to market, but with just $2,359 in cash which makes up all of the reported assets of Zenosense as of June 30, 2014, the marketing plan had better be a strong one if investors who fail to research ZENO are going to buy long and hope for $1.
Looking for the Best Penny Stocks to Buy?
Click HERE To Receive FREE Penny Stock Alerts
About ZENO Stock
Zenosense, Inc. is a development stage company was designed to provide a third party with capital for the development of the sensory technology for a methicillin resistant Staphylococcus aureus / Staphylococcus aureus (“MRSA/SA”) detection device and a cancer detective device and other improvements and variations to the products (the “Sgenia Products”) to be used in the hospital and health care environments in exchange for a worldwide, exclusive license to manufacture, market and sell the resulting products.
Click here to view the SEC filings for ZENO.
Click here to view the website for Zenosense.
Authorized: 500,000,000
Issued and Outstanding: 48,939,797
Last 5 Trading Sessions:
| Date | Open | High | Low | Last | Change | % Chg | Volume |
| 09/23/14 | 0.3800 | 0.3800 | 0.3550 | 0.3600 | -0.0200 | -5.26% | 118,800 |
| 09/22/14 | 0.3600 | 0.3800 | 0.3600 | 0.3800 | +0.0100 | +2.70% | 209,500 |
| 09/19/14 | 0.3700 | 0.3700 | 0.3500 | 0.3700 | +0.0100 | +2.78% | 173,700 |
| 09/18/14 | 0.3500 | 0.3800 | 0.3300 | 0.3600 | +0.0200 | +5.88% | 396,800 |
| 09/17/14 | 0.3300 | 0.3400 | 0.3200 | 0.3400 | +0.0200 | +6.25% | 222,500 |
Bottom Line:
ZENO stock is an under-the-radar promoted penny stock right now and might have already seen its peak when it tried to break past 0.50 at the very start of September. Seeing as how there are more than enough shares out there for volume to exceed 1,000,000 in a session, these appear to be the early days for ZENO which might just be worth flipping for a 0.10 or better rather than thumbing your nose at what’s obviously going to be a winter season promotion.
Stay Connected With Us:
[gravityform id=”6″ name=”Post” title=”false”]
(We are 100% Anti-Spam and will never rent or sell your information) Although many of our picks go up 100, 200% even 4,000%, there is always the chance a stock could move lower.
Please read and understand our rules very carefully:
1. Penny Stocks can be very dangerous, unless you understand the risk involved with them do not try to trade them. Many go up fast and can drop just as fast;
2. Do not risk too much in one company. You can lose it all very quickly;
3. Do not “marry” any one stock. Recognize if you are wrong about a stock, cut your losses and move on to the next stock; and
4. Always use stop loss orders. We recommend that you use “trailing stops” in order to protect your profits.
SEP
